Discover the innovative solution to weight management with Mounjaro, now available through our Patient Group Direction (PGD) service. Mounjaro, a cutting-edge medication, is designed to support individuals on their weight loss journey, offering a new pathway to achieving and maintaining a healthy weight.

Key Features of Mounjaro for Weight Loss:

Effective Weight Management: Mounjaro works by regulating appetite and food intake, helping you to feel fuller for longer and reducing the urge to overeat.
Convenient Administration: Administered through injection, Mounjaro is a practical option for those seeking an alternative to oral weight loss medications.
Tailored to Your Needs: Available under our PGD service, Mounjaro is prescribed after a thorough assessment by our qualified healthcare professionals, ensuring it's suitable for your specific health profile.

Why Choose Our PGD Service for Mounjaro?

Our PGD service allows for the direct supply of Mounjaro to eligible patients without the need for a traditional prescription. This service is guided by strict protocols to ensure patient safety and efficacy of treatment.

Who Can Benefit?

Mounjaro is recommended for adults struggling with weight management, particularly those who have not achieved their desired weight loss through diet and exercise alone. It is an excellent option for individuals looking for a scientifically backed treatment to complement their weight loss efforts.

Getting Started:

To access Mounjaro through our PGD service, start by completing our online consultation. Our team of healthcare professionals will review your information to determine if Mounjaro is the right choice for you.

What are the service inclusion criteria?*

Mounjaro KwickPen is suitable for a specific group of individuals who meet the following criteria:

Age Range: People aged between 18 and 84 years.
BMI Threshold: People with an initial Body Mass Index (BMI) of 30 kg/m² or greater qualify for Mounjaro.
Failed Previous Weight Management Attempts: The pen is intended for people for whom prior attempts at weight reduction, including supervised diet, behaviour modification, and increased physical activity, have not resulted in a practical and sustainable reduction in weight.
Weight-Related Comorbidities: People with an initial BMI of 27 kg/m² or greater are also eligible if they have at least one weight-related comorbidity. These comorbidities may include, but are not limited to:
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Cardiovascular disease
- Type 2 diabetes mellitus

What will happen once I have answered the questions in the form?

A pharmacist trained to provide this private service will assess the form and call you to discuss the answers you provided with you.

Please note

You should select the strength of Mounjaro recommended in your personal treatment plan, starting with the 2.5 mg. If you have doubts about this, please ask our pharmacist before proceeding with your order on pharmacy@medino.com.

We may need to identify the intended user with an identity check. More information about this will be provided during the consultation.

Patient information leaflet

Over The Counter (OTC)

Ingredients

Each dose contains 12.5mg of tirzepatide in 0.6 ml solution.

Other ingredients: Sodium phosphate dibasic heptahydrate, Sodium chloride, Concentrated hydrochloric acid, and sodium hydroxide (for pH adjustment), Water for injections

Usage and Instructions

Inject 12.5mg subcutaneously once per week for 4 weeks (28 days).

Warnings

Injection site:
- It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.
Missed dose: If you miss a dose of Mounjaro and,
- If no more than 4 days have passed since your missed dose, administer it as soon as you recall. Continue with your next injection on the regularly planned day.
- If it has been over 4 days since the missed dose, omit the missed dose. Proceed with your next injection on the regularly scheduled day.
Changing day of injection:
- The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.
Storage:
- Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in original package to protect from light.
- Mounjaro may be stored unrefrigerated for up to 21 cumulative days at a temperature not above 30 °C and then the pre-filled pen must be discarded.

Acute Pancreatitis Concerns with Tirzepatide:
- Not studied in patients with a history of pancreatitis; caution advised.
- Reported cases in patients treated with tirzepatide.
- Discontinue if pancreatitis is suspected; do not restart if confirmed.
Hypoglycemia Risk in Type 2 Diabetes:
- Increased risk when combined with insulin secretagogues or insulin.
- Dose adjustment of insulin or secretagogues may be necessary.
Severe Gastrointestinal Disease Caution:
- Use with caution in patients with severe gastrointestinal diseases, including severe gastroparesis.
Diabetic Retinopathy Caution:
- Use with caution in patients with diabetic retinopathy; appropriate monitoring is advised.
Elderly Patients:
- Very limited data for patients aged ≥85 years, for which is contraindicated.
Sodium Content:
- Contains less than 1 mmol sodium (23 mg) per dose, essentially 'sodium-free'.
Interaction with Other Medicinal Products:
- Delays gastric emptying, affecting absorption of oral medications.
- Monitor closely, especially with medications having a narrow therapeutic index.
Specific Medication Interactions:
- Oral Contraceptives: Reduction in the blood concentration observed; alternative contraceptive method (barriers) recommended for fertile women starting tirzepatide therapy.
Pregnancy and Lactation:
- Limited data on use in pregnant women; not recommended.
- Unknown if excreted in human milk; weigh benefits against risks.
- Effect on human fertility unknown; no direct harmful effects in animal studies.
Effects on Driving and Machine Use:
- Negligible influence, but precautions are advised when used with sulphonylurea or insulin to avoid hypoglycemia.

Side Effects

System organ class	Very common	Common	Uncommon
Immune system disorders	Hypersensitivity reactions	Anaphylactic reaction (1), angioedema (1)
Metabolism and nutrition disorders	Hypoglycaemia (1) when used with sulphonylurea or insulin	Hypoglycaemia (1) when used with metformin and SGLT2ia, decreased appetite	Hypoglycaemia (1) when used with metformin, weight decreased
Nervous system disorders		Dizziness (2)
Vascular disorders		Hypotension related events (2)
Gastrointestinal disorders	Nausea, diarrhoea, vomiting (2), constipation (2)	Abdominal pain, vomiting (1), dyspepsia, constipation (1), abdominal distention, eructation, flatulence, gastroesophageal reflux disease	Cholelithiasis, acute pancreatitis, Cholecystitis (2)
Skin and subcutaneous tissue disorders		Hair loss (2)
General disorders and administration site conditions	Fatigue, injection site reactions (1)	Injection site pain
Investigations	Heart rate increased (1), lipase increased, amylase increased (1)	Blood calcitonin increased, amylase increased (2), heart rate increased (2)

Notes:

(1) Indicates that the condition is dose-dependent.
(2) Indicates that the condition is more likely to occur in specific populations.
Fatigue includes both general fatigue and physical weakness.